ArticleScientific reports2020
A single unified model for fitting simple to complex receptor response data.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- ZBP1 in Neuroinflammation and Neurodegeneration: Z-Nucleic-Acid Sensing, RHIM Signalling and Therapeutic Targeting.International journal of molecular sciences · 2026Review
- Deoxynojirimycin derivatives as potent α-glucosidase inhibitors: in silico ADMET evaluation, molecular dynamics and in vitro validation studies.Molecular diversity · 2026Article
- The ability of SABRE, a new quantitative receptor function model, to quantify receptor binding from even challenging concentration-effect data with a single unified fit.Frontiers in pharmacology · 2026Article
- Bioassay-Guided Isolation and Active Compounds Identification of the AntiDiabetic Fractions ofMolecules (Basel, Switzerland) · 2025Article
- Application of the Richards function to serum antibody titration.Frontiers in immunology · 2025Article
- Quantification of signal amplification for receptors: theFrontiers in pharmacology · 2025Article
- The flexibility of SABRE, a new quantitative receptor function model, when fitting challenging concentration-effect data.Frontiers in pharmacology · 2025Article
- Commentary: The flexibility of SABRE, a new quantitative receptor function model, in fitting challenging concentration-effect data.Frontiers in pharmacology · 2025Article
- Cooperative Gating of a KJournal of the American Chemical Society · 2024Article
- Characterizing Aptamer Interaction with the Oncolytic Virus VV-GMCSF-Lact.Molecules (Basel, Switzerland) · 2024Article
- Nanomechanoelectrical approach to highly sensitive and specific label-free DNA detection.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Quantitative receptor model for responses that are left- or right-shifted versus occupancy (are more or less concentration sensitive): the SABRE approach.Frontiers in pharmacology · 2023Article
- Quantification of receptor binding from response data obtained at different receptor levels: a simple individual sigmoid fitting and a unified SABRE approach.Scientific reports · 2022Article
- Methylene Blue Is a Nonspecific Protein-Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Inhibition mechanism of alpha-amylase, a diabetes target, by a steroidal pregnane and pregnane glycosides derived fromFrontiers in molecular biosciences · 2022Article
- RobustFrontiers in immunology · 2022Article
- Regioselective One-Pot Synthesis of Hydroxy-(Frontiers in bioengineering and biotechnology · 2022Article
- Discovery of μ,δ-Opioid Receptor Dual-Biased Agonists That Overcome the Limitation of Prior Biased Agonists.ACS pharmacology & translational science · 2021Article
- Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2.ACS infectious diseases · 2021Article
- Methylene Blue Inhibits the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction-a Mechanism that can Contribute to its Antiviral Activity Against COVID-19.Frontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The fitting of complex receptor-response data where fractional response and occupancy do not match is challenging. They encompass important cases including (a) the presence of "receptor reserve" and/or partial agonism, (b) multiple responses assessed at different vantage points along a pathway, (c) responses that are different along diverging downstream pathways (biased agonism), and (d) constitutive activity. For these, simple models such as the well-known Clark or Hill equations cannot be used. Those that can, such as the operational (Black&Leff) model, do not provide a unified approach, have multiple nonintuitive parameters that are challenging to fit in well-defined manner, have difficulties incorporating binding data, and cannot be reduced or connected to simpler forms. We have recently introduced a quantitative receptor model (SABRE) that includes parameters for Signal Amplification (γ), Binding affinity (K
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.